Ascend Bundle

Three single vials from unrelated research areas: retatrutide, an investigational GLP-1/GIP/glucagon receptor agonist studied in metabolic research; GHK-Cu, a copper peptide studied in skin research; and MT-1 (afamelanotide), an MC1R agonist studied in pigmentation research. The catalog states no rationale for the grouping, and no component entry describes a shared mechanism.

Retatrutide's phase 3 TRIUMPH-1 trial (2,339 adults, 80 weeks) reported average weight loss of 28.3% at the top dose; it is not yet approved. GHK-Cu's human evidence is small, mostly industry-run cream studies on skin thickness and wrinkles, with no human data outside topical use. MT-1's approval rests on a slow-release implant for a rare light-sensitivity disease; the loose peptide is short-lived in the body, and non-implant forms have no trials. No study has tested any pairing of these three.

Nausea was reported from two sources: retatrutide (42% vs 15% on placebo) and Scenesse (19% vs 14%). In trials, retatrutide raised heart rate and caused skin burning or tingling in up to about one in five participants in higher-dose arms; MT-1 is associated with darkening of skin, moles and freckles, and non-topical GHK-Cu products have been linked to site irritation, infections and raised liver enzymes, so skin symptoms are hard to attribute. MT-1's EU label cautions about reduced liver or kidney function, and rare anaphylaxis has been reported.

Retatrutide is investigational, not approved anywhere and not compoundable (Lilly plans to file with FDA in the first quarter of 2027); FDA has warned research sellers marketing it for people, and Lilly sued six sellers in 2026. MT-1 is approved only as the Scenesse implant for erythropoietic protoporphyria, and injectable GHK-Cu has no approval or compounding pathway. No component is named on the 2026 WADA list.